Governance

Board

Jan van der Hoeven – BIOX Biosciences

Jan is an investor in the field of Life Sciences. He has more than 30 years of operating, scientific and financial experience in private equity backed life sciences companies. He has been involved in a number of successful international merger & acquisition deals. He is a Toxicologist with a very successful track record. He is active in a number of funds to stimulate Life Sciences Companies. 

 

Eveline Hogenkamp – Beukenlaantje

Eveline is an experienced Business leader, as former MD of a business unit in the pharma industry, with a solid background in finance and supply chain, with over 13 years of experience in life sciences in both pharma and medical devices. She has a broad experience in mergers, acquisitions and integration. Since 1 year she is involved in life science businesses to accelerate their potential.

 

Cees de Wolff – LUPUS Ventures

Cees is co-owner of De Wolff Verenigde Bedrijven. Cees brings 30 years of no-nonsense hands-on business experience and serves as advisor and/or board member in a large number of innovative companies. He has a successful track record in wind power business and merger and acquisition deals. He is active in a number of funds to stimulate Life Sciences Companies.

 

Advisory Board

Wiebe Olijve (PhD)

Wiebe Olijve is an experienced research leader who has developed a range of biotech applications throughout his career. Until recently he was the CEO and co-founder of BioNovion (now Aduro Biotech Europe). Before that, he was vice president of Schering-Plough Biopharma (now Merck Research Laboratories). He also founded the Organon Research Center in Cambridge, Massachusetts, where antibodies against oncological and auto-immune diseases were developed. During this time, Dr Olijve led the project that discovered pembrolizumab (Keytruda) – a humanized antibody used in cancer immunotherapy. He also spent many years leading pioneering research programs at Organon, using genomic and bioinformatics approaches to identify therapeutic targets. These endeavors advanced research in the Netherlands and the United States. Dr Olijve has been a professor of Applied Biology at Radboud University in Nijmegen since 1990.

Bert Pauli

Coming soon.

Dr. Bob Pinedo, M.D., Ph.D., Professor of Medical Oncology (retired), Director of the VU University Medical Center (VUmc) Cancer Center Amsterdam

Herbert M Pinedo, M.D., Ph.D., is Professor of Medical Oncology, Chairman of the Board at the Cancer Center Amsterdam, Free University of Amsterdam. He is a member of the British Royal Society of Medicine and The Royal Dutch Academy of Science and Arts, where he is Chairman of the Board of the Medical Division. He has served on the boards of a number of pharmaceutical companies. He founded the New Drug Development Office – Oncology, which coordinates early clinical trials with anticancer agents internationally.

He was the first President of the Federation of European Cancer Societies, and Past President to the European Society of Medical Oncology.

He co-founded the Annals of Oncology and The Oncologist and is the Co-Editor of Current Opinion in Anticancer Drugs. He serves on numerous editorial boards including Clinical Cancer Research, and Journal of Clinical Oncology. He has authored more than 600 peer-reviewed international publications and more than 120 chapters, invited papers or proceedings.

He has received many international awards including the prestigious Josef Steiner award and has been decorated by H.M. Queen Beatrice of the Netherlands with the prestigious Knight of the Order of the Netherlands Lion.